A Phase 2a/2b Randomized, Placebo-Controlled Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants with Rifampicin-Susceptible Pulmonary TB ( A5397/HVTN 603)

The study is a double-blinded, placebo-controlled study with a Phase 2a  and a Phase 2b component evaluating safety and immunogenicity of ID93 + GLA-SE, as well as tuberculosis (TB) outcomes. Participants with TB who are receiving locally provided standard of care (SOC) TB treatment will be randomized to receive ID93 + GLA-SE or placebo.